Regeneron to acquire 23andMe for US$256m after bankruptcy, aims to leverage genetic data

AI Summary

Regeneron Pharmaceuticals will acquire bankrupt genetic testing company 23andMe for US$256 million. The deal grants Regeneron access to data from millions of 23andMe clients. 23andMe, once valued at US$6 billion, struggled with declining sales after a 2023 data breach affecting nearly seven million accounts. Regeneron aims to leverage this genetic data for research to improve disease treatment and prevention. The acquisition requires court approval and is expected to close in Q3 2025.